OncoTherapy Science, Inc. (FRA:30O)

Market Cap	39.53M +1.8%
Revenue (ttm)	4.41M +7.7%
Net Income	-4.96M
EPS	-0.02
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.0730
Previous Close	0.0840
Day's Range	0.0730 - 0.0730
52-Week Range	0.0640 - 0.1940
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 7, 2026

About OncoTherapy Science

OncoTherapy Science, Inc. engages in research and development of anti-body drugs; and the genome analysis of cancer, liquid biopsy, and development of new immunotherapy in Japan. Its development pipeline includes OTS167, a small molecular compound that targets the maternal embryonic leucine zipper kinase inhibitor that is in Phase I/II clinical trials for the treatment of acute myeloid leukemia, as well as in Phase I clinical trials for the treatment of breast cancer; and OTS964, a small molecule TOPK inhibitor currently under non-clinical stag...

• Industry: Commercial Physical and Biological Research
• Founded: 2001
• Employees: 47
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 30O

Financial Performance

In fiscal year 2026, OncoTherapy Science's revenue was 808.00 million, an increase of 7.73% compared to the previous year's 750.00 million. Losses were -910.00 million, 11.7% more than in 2025.

Financial numbers in JPY

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Jun 26, 2026

Data Sources Report a data error